This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 Jan 5;393(10166):3-5.

doi: 10.1016/S0140-6736(18)32824-1. Epub 2018 Nov 10.

Pump, pipes, and filter: do SGLT2 inhibitors cover it all?

Subodh Verma¹, Peter Jüni², C David Mazer²

Affiliations

Affiliations

¹ Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto M5B 1W8, ON, Canada; Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada. Electronic address: vermasu@smh.ca.
² Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada.

PMID: 30424891
DOI: 10.1016/S0140-6736(18)32824-1

Comment

Pump, pipes, and filter: do SGLT2 inhibitors cover it all?

Subodh Verma et al. Lancet. 2019.

. 2019 Jan 5;393(10166):3-5.

doi: 10.1016/S0140-6736(18)32824-1. Epub 2018 Nov 10.

Authors

Subodh Verma¹, Peter Jüni², C David Mazer²

Affiliations

¹ Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto M5B 1W8, ON, Canada; Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada. Electronic address: vermasu@smh.ca.
² Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada.

PMID: 30424891
DOI: 10.1016/S0140-6736(18)32824-1

No abstract available

PubMed Disclaimer

Comment on

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. Zelniker TA, et al. Lancet. 2019 Jan 5;393(10166):31-39. doi: 10.1016/S0140-6736(18)32590-X. Epub 2018 Nov 10. Lancet. 2019. PMID: 30424892

Similar articles

Diabetes: Further insights into SGLT2 inhibitors.
Fernández-Ruiz I. Fernández-Ruiz I. Nat Rev Cardiol. 2018 Jan;15(1):2-3. doi: 10.1038/nrcardio.2017.198. Epub 2017 Nov 30. Nat Rev Cardiol. 2018. PMID: 29188808 No abstract available.
Canagliflozin: Cui Bono?
Cavender MA, Kosiborod M. Cavender MA, et al. Circulation. 2018 Jan 23;137(4):335-337. doi: 10.1161/CIRCULATIONAHA.117.032198. Epub 2017 Nov 13. Circulation. 2018. PMID: 29133603 No abstract available.
Leaving the Glucocentric View: Can SGLT2 Inhibitors Halt CVD in Patients With Type 2 Diabetes?
Marx N. Marx N. J Am Coll Cardiol. 2017 Aug 8;70(6):713-714. doi: 10.1016/j.jacc.2017.06.037. J Am Coll Cardiol. 2017. PMID: 28774376 No abstract available.
Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
Lee S. Lee S. Crit Pathw Cardiol. 2017 Sep;16(3):93-95. doi: 10.1097/HPC.0000000000000125. Crit Pathw Cardiol. 2017. PMID: 28742644 Review.
The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
Garcia-Ropero A, Badimon JJ, Santos-Gallego CG. Garcia-Ropero A, et al. Expert Opin Drug Metab Toxicol. 2018 Dec;14(12):1287-1302. doi: 10.1080/17425255.2018.1551877. Epub 2018 Nov 29. Expert Opin Drug Metab Toxicol. 2018. PMID: 30463454 Review.

See all similar articles

Cited by

Synergistically improved cardiovascular outcomes in type 2 diabetes mellitus patients with combined treatment of SGLT-2 inhibitors and pioglitazone.
Li YR, Wang CC, Liu CH, Yen CL, Wu VC, Huang EJ, Lee CY, Hsiao CC. Li YR, et al. Front Endocrinol (Lausanne). 2024 Aug 30;15:1420485. doi: 10.3389/fendo.2024.1420485. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39280016 Free PMC article.
Sodium-Glucose Cotransporter-2 Inhibitors and Nephritis Among Patients With Systemic Lupus Erythematosus.
Yen FS, Wang SI, Hsu CC, Hwu CM, Wei JC. Yen FS, et al. JAMA Netw Open. 2024 Jun 3;7(6):e2416578. doi: 10.1001/jamanetworkopen.2024.16578. JAMA Netw Open. 2024. PMID: 38865122 Free PMC article.
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium-Glucose Cotransporter 2 Inhibitors.
Verma S, Mudaliar S, Greasley PJ. Verma S, et al. Adv Ther. 2024 Jan;41(1):92-112. doi: 10.1007/s12325-023-02652-5. Epub 2023 Nov 9. Adv Ther. 2024. PMID: 37943443 Free PMC article. Review.
Exploring the comparative cardiovascular death benefits of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring.
Ghosal S, Sinha B. Ghosal S, et al. Front Endocrinol (Lausanne). 2023 Jul 3;14:1168755. doi: 10.3389/fendo.2023.1168755. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37469980 Free PMC article.
Benefits of Taking Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: A Systematic Review.
Sarker A, Ramesh AS, Munoz C, Jamil D, Tran HH, Mansoor M, Butt SR, Satnarine T, Ratna P, Hamid P. Sarker A, et al. Cureus. 2022 Sep 12;14(9):e29069. doi: 10.7759/cureus.29069. eCollection 2022 Sep. Cureus. 2022. PMID: 36249645 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information